{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-24-009750","form_type":"8-K","ticker":"BPTH","cik":"0001133818","company_name":"BIO-PATH HOLDINGS, INC.","filed_at":"2024-07-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:12.257237+00:00","generated_at":"2026-05-31T21:41:20.560920+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Bio-Path provides clinical update; expands prexigebersen into obesity preclinical studies","bullets":["Phase 2 AML trial paused for interim analysis; expects to complete enrollment in cohorts 1&2 over 18 months.","Phase 1/1b BP1001-A advanced to dose level 2; expects dose level 3 by year-end.","Phase 1/1b BP1002 completed second dose cohort (40 mg/m2); advancing to dose level 3 in Q4 2024.","Developed molecular biomarkers for prexigebersen; preparing preclinical obesity studies.","Phase 1 BP1002 in lymphoma/CLL enrolling second dose cohort; results expected year-end."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-24-009750","json":"https://secwatch.observer/filing/0001558370-24-009750.json","markdown":"https://secwatch.observer/filing/0001558370-24-009750.md","text":"https://secwatch.observer/filing/0001558370-24-009750.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1133818/000155837024009750/0001558370-24-009750-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1133818/000155837024009750/bpth-20240708x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T21:41:20.560920+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}